MMPs: a novel drug target for schizophrenia

Bibliography

• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, just the facts 4. Clinical features and conceptualization. Schizophr Res 2009;110:1-23
   PubMed Web of Science ®Google Scholar
• Schizophrenia. World health organisation. Available from: http://www.who.int/mental_health/management/schizophrenia/en/ [Last accessed 13 March 2014]
   Google Scholar
• Ciobica A, Padurariu M, Dobrin I, et al. Oxidative stress in schizophrenia - focusing on the main markers. Psychiatr Danub 2011;23:237-45
   PubMed Web of Science ®Google Scholar
• Jones CA, Watson DJ, Fone KC. Animal models of schizophrenia. Br J Pharmacol 2011;164:1162-94
   PubMed Web of Science ®Google Scholar
• Wong AH, Van Tol HH. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 2003;27:269-306
   PubMed Web of Science ®Google Scholar
• Monji A, Kato T, Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009;63:257-65
   PubMed Web of Science ®Google Scholar
• O’Donnell P. Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models. Schizophr Bull 2011;37:484-92
   PubMed Web of Science ®Google Scholar
• Snyder MA, Gao WJ. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci 2013;7:31
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012;37:4-15
   PubMed Web of Science ®Google Scholar
• Berretta S. Astrocytes in the pathophysiology of schizophrenia: abnormal expression of extracellular matrix molecules. Schizophr Res 2008;102:11
   Google Scholar
• Shan D, Yates S, Roberts RC, McCullumsmith RE. Update on the neurobiology of schizophrenia: a role for extracellular microdomains. Minerva Psichiatr 2012;53:233-49
   Google Scholar
• Spangaro M, Bosia M, Zanoletti A, et al. Cognitive dysfunction and glutamate reuptake: effect of EAAT2 polymorphism in schizophrenia. Neurosci Lett 2012;522:151-5
   Google Scholar
• Huxley-Jones J, Foord SM, Barnes MR. Drug discovery in the extracellular matrix. Drug Discov Today 2008;13:685-94
   PubMedGoogle Scholar
• Galtrey CM, Fawcett JW. The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system. Brain Res Rev 2007;54:1-18
   PubMedGoogle Scholar
• Berretta S. Extracellular matrix abnormalities in schizophrenia. Neuropharmacology 2012;62:1584-97
   PubMed Web of Science ®Google Scholar
• Wade A, McKinney A, Phillips JJ. Matrix regulators in neural stem cell functions. Biochim Biophys Acta 2014;1840(8):2520-5
   Google Scholar
• Baeten KM, Akassoglou K. Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke. Dev Neurobiol 2011;71:1018-39
   PubMed Web of Science ®Google Scholar
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39
   PubMed Web of Science ®Google Scholar
• Pantazopoulos H, Woo TU, Lim MP, et al. Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch Gen Psychiatry 2010;67:155-66
   PubMed Web of Science ®Google Scholar
• Faissner A, Pyka M, Geissler M, et al. Contributions of astrocytes to synapse formation and maturation - Potential functions of the perisynaptic extracellular matrix. Brain Res Rev 2010;63:26-38
   PubMed Web of Science ®Google Scholar
• Costa E, Davis J, Grayson DR, et al. Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. Neurobiol Dis 2001;8:723-42
   PubMed Web of Science ®Google Scholar
• Sinagra M, Verrier D, Frankova D, et al. Reelin, very-low-density lipoprotein receptor, and apolipoprotein E receptor 2 control somatic NMDA receptor composition during hippocampal maturation in vitro. J Neurosci 2005;25:6127-36
   Google Scholar
• Szabo KA, Ablin RJ, Singh G. Matrix metalloproteinases and the immune response. Clin Appl Immunol Rev 2004;4:295-319
   Google Scholar
• Ganea E, Trifan M, Laslo AC, et al. Matrix metalloproteinases: useful and deleterious. Biochem Soc Trans 2007;35:689-91
   PubMed Web of Science ®Google Scholar
• Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009;8:205-16
   PubMed Web of Science ®Google Scholar
• Konnecke H, Bechmann I. The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas. Clin Dev Immunol 2013;2013:914104
   PubMedGoogle Scholar
• Nissinen L, Kahari VM. Matrix metalloproteinases in inflammation. Biochim Biophys Acta 2014;1840(8):2571-80
   PubMed Web of Science ®Google Scholar
• Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008;29:290-308
   PubMed Web of Science ®Google Scholar
• Trysberg E, Blennow K, Zachrisson O, Tarkowski A. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther 2004;6:R551-6
   Google Scholar
• Kim YS, Joh TH. Matrix metalloproteinases, new insights into the understanding of neurodegenerative disorders. Biomol Ther (Seoul) 2012;20:133-43
   Google Scholar
• Domenici E, Wille DR, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010;5:e9166
   PubMed Web of Science ®Google Scholar
• Yamamori H, Hashimoto R, Ishima T, et al. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett 2013;556:37-41
   PubMed Web of Science ®Google Scholar
• Kucukali CI, Aydin M, Ozkok E, et al. Do schizophrenia and bipolar disorders share a common disease susceptibility variant at the MMP3 gene? Prog Neuropsychopharmacol Biol Psychiatry 2009;33:557-61
   Google Scholar
• Fitch MT, Silver J. CNS injury, glial scars, and inflammation: inhibitory extracellular matrices and regeneration failure. Exp Neurol 2008;209:294-301
   PubMed Web of Science ®Google Scholar
• Lively S, Schlichter LC. The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasion. J Neuroinflammation 2013;10:75
   Google Scholar
• Kato TA, Hayakawa K, Monji A, Kanba S. Missing and possible link between neuroendocrine factors, neuropsychiatric disorders, and microglia. Front Integr Neurosci 2013;7:53
   Google Scholar
• Van den Eynde K, Missault S, Fransen E, et al. Hypolocomotive behaviour associated with increased microglia in a prenatal immune activation model with relevance to schizophrenia. Behav Brain Res 2014;258:179-86
   Google Scholar
• Ogier C, Bernard A, Chollet AM, et al. Matrix metalloproteinase-2 (MMP-2) regulates astrocyte motility in connection with the actin cytoskeleton and integrins. Glia 2006;54:272-84
   PubMedGoogle Scholar
• Ganzinelli S, Borda E, Sterin-Borda L. Autoantibodies from schizophrenia patients induce cerebral cox-1/iNOS mRNA expression with NO/PGE2/MMP-3 production. Int J Neuropsychopharmacol 2010;13:293-303
   Google Scholar
• Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res 2007;85:2813-23
   PubMed Web of Science ®Google Scholar
• Lin A, Kenis G, Bignotti S, et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998;32:9-15
   PubMed Web of Science ®Google Scholar
• McCawley LJ, Matrisian LM. Matrix metalloproteinases: they’re not just for matrix anymore!. Curr Opin Cell Biol 2001;13:534-40
   PubMed Web of Science ®Google Scholar
• Pedrini M, Massuda R, Fries GR, et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 2012;46:819-24
   PubMed Web of Science ®Google Scholar
• Kubistova A, Horacek J, Novak T. Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatr Danub 2012;24(Suppl 1):S153-6
   Google Scholar
• Haylock-Jacobs S, Keough MB, Lau L, Yong VW. Chondroitin sulphate proteoglycans: extracellular matrix proteins that regulate immunity of the central nervous system. Autoimmun Rev 2011;10:766-72
   Google Scholar
• Ralay Ranaivo H, Hodge JN, Choi N, Wainwright MS. Albumin induces upregulation of matrix metalloproteinase-9 in astrocytes via MAPK and reactive oxygen species-dependent pathways. J Neuroinflammation 2012;9:68
   Google Scholar
• Rybakowski JK. Matrix Metalloproteinase-9 (MMP9)-A Mediating enzyme in cardiovascular disease, cancer, and neuropsychiatric disorders. Cardiovasc Psychiatry Neurol 2009;2009:904836
   PubMedGoogle Scholar
• Rybakowski JK, Skibinska M, Kapelski P, et al. Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia. Schizophr Res 2009;109:90-3
   PubMed Web of Science ®Google Scholar
• Han H, He X, Tang J, et al. The C(-1562)T polymorphism of matrix metalloproteinase-9 gene is associated with schizophrenia in China. Psychiatry Res 2011;190:163-4
   Google Scholar
• Michaluk P, Mikasova L, Groc L, et al. Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin beta1 signaling. J Neurosci 2009;29:6007-12
   PubMedGoogle Scholar
• Milward EA, Fitzsimmons C, Szklarczyk A, Conant K. The matrix metalloproteinases and CNS plasticity: an overview. J Neuroimmunol 2007;187:9-19
   PubMed Web of Science ®Google Scholar
• Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008;320:539-43
   PubMed Web of Science ®Google Scholar
• Krstic D, Rodriguez M, Knuesel I. Regulated proteolytic processing of Reelin through interplay of tissue plasminogen activator (tPA), ADAMTS-4, ADAMTS-5, and their modulators. PLoS One 2012;7:e47793
   Google Scholar
• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74
   PubMed Web of Science ®Google Scholar
• Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258-65
   PubMed Web of Science ®Google Scholar
• Begemann MJ, Dekker CF, van Lunenburg M, Sommer IE. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res 2012;141:179-84
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Gavrilidis E, Wang W, et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry 2014. [Epub ahead of print]
   PubMedGoogle Scholar